发明名称 Anti-cMET antibody
摘要 Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
申请公布号 US9469691(B2) 申请公布日期 2016.10.18
申请号 US201414248741 申请日期 2014.04.09
申请人 PIERRE FABRE MEDICAMENT 发明人 Goetsch Liliane;Wurch Thierry;Bes Cédric
分类号 A61K39/395;C07K16/28;A61K45/06;A61K31/337;A61K31/517;A61K31/5377;A61K31/555;A61K31/7068;A61K33/24;A61K39/00 主分类号 A61K39/395
代理机构 Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 代理人 Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
主权项 1. A monoclonal chimeric or humanized anti-cMet antibody comprising: a heavy chain comprising complementarity determining regions (CDR) CDR-H1, CDR-H2, and CDR-H3 comprising amino acid sequences SEQ ID Nos. 1, 2, and 3, respectively; a light chain comprising CDR-L1, CDR-L2, and CDR-L3 comprising amino acid sequences SEQ ID Nos. 5, 6, and 7, respectively; and a modified hinge region comprising the amino acid sequence SEQ ID No. 26.
地址 Boulogne-Billancourt FR